Collaboration, License and Purchase Agreements - Narrative 2 (Details) (USD $)	0 Months Ended	12 Months Ended					1 Months Ended
	Nov. 03, 2013 Altus Formulation Inc. Development and Option Agreement [Member]	Dec. 31, 2013 Altus Formulation Inc. Development and Option Agreement [Member]	Dec. 31, 2011 Durect Development and License Agreement [Member]	Dec. 31, 2011 Durect Development and License Agreement [Member] Minimum [Member]	Dec. 31, 2011 Durect Development and License Agreement [Member] Research and Development Expense [Member]	Dec. 31, 2013 Alkermes License Agreement (formerly Elan Pharma International Limited) [Member]	Oct. 31, 2013 Alkermes License Agreement (formerly Elan Pharma International Limited) [Member] Other Assets [Member]	May 31, 2012 Alkermes License Agreement (formerly Elan Pharma International Limited) [Member] Research and Development Expense [Member]	Aug. 30, 2011 Alkermes License Agreement (formerly Elan Pharma International Limited) [Member] Research and Development Expense [Member]	Nov. 30, 2007 Alkermes License Agreement (formerly Elan Pharma International Limited) [Member] Research and Development Expense [Member]
Research and Development Arrangement, Contract to Perform for Others [Line Items]
Non Refundable Up Front Fee Payment	$ 750,000
Maximum Additional Payments On Achievement Of Series Of Milestones		3,500,000
Agreement termination notice period		30 days				12 months
Non-refundable up-front payment					2,250,000					500,000
Milestone payments made							2,750,000	1,000,000	750,000
Minimum future milestone payments			103,000,000
Annual external development expense obligation				$ 1,000,000
External development expense obligation period			12 months
Royalty agreement term			15 years			15 years
Automatic extension of arrangement term						3 years